drugset / Trial / NCT06270030

Safety, Tolerability and Pharmacokinetics of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Chinese With Presbyopia

NCT06270030

RandomizedParallel-groupSingle-blindTreatment

Summary

Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LNZ101 and LNZ100 Ophthalmic Solutions in Chinese Healthy Adult Subjects with Presbyopia

Timeline

Start
2024-03-04
Primary completion
2024-04-10
Completion
2024-04-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Aceclidine Small molecule Other
Subject Brimonidine Small molecule Other

Indications